Effect of Incremental Tazobactam Concentrations on the Bactericidal Activity of Piperacillin Against ESBL-producing Enterobacterales Clinical Isolates Causing Bacteraemia

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2024 Jul 17

PMID 39017998

Authors

Marta Palombo

Milo Gatti

Benedetta Secci

Pier Giorgio Cojutti

Federico Pea

Davide Gibellini

Paolo Gaibani

Affiliations

Soon will be listed here.

Abstract

We evaluated the activity of piperacillin in relation to INCREASING TAZOBACTAM CONCENTRATION against ESBL-producing Enterobacterales collected from patients with bacteraemia. Increasing tazobactam concentration (4, 12 or 24 mg/L) exerted a reduction of piperacillin MICs under the clinical breakpoint in a concentration-dependent manner (0%, 60% and 90% of clinical isolates). Also, activity of piperacillin/tazobactam based at higher achievable serum concentrations (123/14 mg/L) is needed to reduce the bacterial growth in 92% of ESBL-producers. CHANGES IN THE PIPERACILLIN MIC IN RELATION TO INCREASING TAZOBACTAM SUGGEST THAT REALTIME TDM COULD BE USED FOR DRIVEN ANTIMICROBIAL THERAPY WITH PIPERACILLIN/TAZOBACTAM IN BSI DUE TO ESBL STRAINS.

References

Peirano G, Pitout J . Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options. Drugs. 2019; 79(14):1529-1541. DOI: 10.1007/s40265-019-01180-3. View

Harris P, Tambyah P, Lye D, Mo Y, Lee T, Yilmaz M . Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA. 2018; 320(10):984-994. PMC: 6143100. DOI: 10.1001/jama.2018.12163. View

Ng T, Khong W, Harris P, De P, Chow A, Tambyah P . Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. PLoS One. 2016; 11(4):e0153696. PMC: 4841518. DOI: 10.1371/journal.pone.0153696. View

Tamma P, Rodriguez-Bano J . The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections. Clin Infect Dis. 2017; 64(7):972-980. PMC: 5848369. DOI: 10.1093/cid/cix034. View

Seo Y, Lee J, Kim Y, Lee S, Lee J, Kim H . Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis. 2017; 17(1):404. PMC: 5463388. DOI: 10.1186/s12879-017-2502-x. View

Zhang W, Yan C, Li S, Fan T, Cao S, Cui B . Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing . Front Cell Infect Microbiol. 2023; 13:1093842. PMC: 10188998. DOI: 10.3389/fcimb.2023.1093842. View

Gatti M, Rinaldi M, Gaibani P, Siniscalchi A, Tonetti T, Giannella M . A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF). J Crit Care. 2023; 76:154301. DOI: 10.1016/j.jcrc.2023.154301. View

Gaibani P, Bussini L, Amadesi S, Bartoletti M, Bovo F, Lazzarotto T . Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient. Microorganisms. 2022; 10(4). PMC: 9025179. DOI: 10.3390/microorganisms10040778. View

Palombo M, Secci B, Bovo F, Gatti M, Ambretti S, Gaibani P . In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing Clinical Isolates. Antibiotics (Basel). 2023; 12(12). PMC: 10740727. DOI: 10.3390/antibiotics12121707. View

10.

Berrino P, Gatti M, Rinaldi M, Brunocilla E, Viale P, Pea F . Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections. Antibiotics (Basel). 2023; 12(9). PMC: 10525318. DOI: 10.3390/antibiotics12091388. View